EpimAb Biotherapeutics, Inc., an innovative startup based in China, has successfully raised an impressive $60 million in a recent financing round, positioning itself at the forefront of the biopharmaceutical landscape. Founded in 2015, EpimAb is harnessing its proprietary FIT-Ig platform, which enables the development of cutting-edge bi-specific antibodies targeting both oncology and immune-oncology indications. The company鈥檚 significant fundraising marks a pivotal moment in its journey, allowing it to advance its promising portfolio of therapies. Among its notable candidates is EMB-01, a cMET/EGFR-inhibitor currently in the CMC development phase, developed in collaboration with the renowned WuXi Apptec. This new capital injection will support EpimAb's ongoing research and development efforts, aiming to bring transformative treatments to patients suffering from aggressive cancers. Additionally, with previous licensing agreements, including those with Kymab and Innovent Biologics, the company is positioned to forge further strategic partnerships, making it an attractive player in the biotech ecosystem. This funding not only strengthens EpimAb's operational capabilities but also underscores the confidence investors have in its innovative approach and the potential impact of its treatments in the ever-evolving field of oncology. As EpimAb Biotherapeutics continues to break new ground, it remains committed to delivering groundbreaking therapies that could reshape the future of cancer treatment.
EpimAb Biotherapeutics Secures $60 Million in Funding to Advance Novel Bi-Specific Antibodies in Oncology
Recently funded 路 $60.0MBiotechnology
Get the full EpimAb Biotherapeutics, Inc. company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
